RecruitingPhase 1NCT05735028

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

A Preliminary Study on the Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Enrollment

8 participants

Start Date

Feb 7, 2024

Study Type

INTERVENTIONAL

Conditions

Lung Cancer

Summary

Lung cancer has a high global cancer morbidity and mortality. At present, PD-1/PD-L1 inhibitors have been approved by FDA to treat different types of lung cancer, but the efficacy is not good. There is an urgent need to develop drugs that can significantly enhance the efficacy of PD-1/PD-L1 inhibitors to enable tumor patients to obtain lasting anti-tumor response. Centipeda minima (CM), as a commonly used traditional Chinese medicine, is relatively safe. Previous studies found that it can inhibit the growth of lung cancer cells. At the level of animal research, the combined use of CM and PD-1/PD-L1 inhibitors produced a stronger anti-lung cancer effect, and did not produce obvious side effects on mice. Based on previous studies, the main purpose of this study was to evaluate the efficacy and safety of PD-1/PD-L inhibitors combined with herbivorous herbivores (CM) in the treatment of lung cancer.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This trial looks at whether adding Centipeda minima (CM) — a traditional Chinese herbal medicine — to PD-1/PD-L1 immunotherapy drugs improves outcomes for people with non-small cell lung cancer (NSCLC). Immunotherapy has become a standard treatment for lung cancer, and this study explores whether the herbal medicine may enhance the immune response or reduce side effects. **You may be eligible if...** - You are 18 to 70 years old - You have non-small cell lung cancer confirmed by biopsy - You are being treated with a PD-1/PD-L1 inhibitor (immunotherapy drug) - Your expected survival is more than 6 months **You may NOT be eligible if...** - You are receiving other traditional Chinese medicine treatments during the study - You have a severe, uncontrolled infection or open wounds - You have significant gastrointestinal problems that prevent you from taking oral medication - You have serious heart disease (such as severe heart failure, uncontrolled arrhythmia, or recent heart attack) - You have an active autoimmune disease or are taking immunosuppressive drugs - You have uncontrolled brain metastases - You are allergic to any of the study drugs Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCentipeda minima+PD-1/PD-L1 inhibitor

Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.

DRUGPD-1/PD-L1 inhibitor

PD-1/PD-L1 inhibitor